Researchers at the Massachusetts Institute of Technology have developed a nanoparticle-based adjuvant that enables injectable polio vaccines to stimulate mucosal immunity in the digestive tract. This breakthrough is critical for global health professionals because it could prevent asymptomatic viral transmission, a capability previously restricted to the riskier oral vaccine. The technology uses lipid nanoparticles to slowly release vitamin A derivatives, offering a promising template for enhancing vaccines against various other pathogens that infect mucosal linings.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





